Lirentelimab is under clinical development by Allakos and currently in Phase II for Peanut Allergy. According to GlobalData, Phase II drugs for Peanut Allergy have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Lirentelimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lirentelimab overview

Lirentelimab (AK002) is under development for the treatment of indolent systemic mastocytosis, chronic urticaria, atopic keratoconjunctivitis, vernal keratoconjunctivitis, peanut allergy severe perennial allergic conjunctivitis and other diseases. The drug candidate is a humanized non-fucosylated anti-Siglec-8 monoclonal antibody (IgG1) that is administered through intravenous and subcutaneous route. It acts by targeting mast cells expressing siglec-8 (Sialic acid binding Ig like Lectin 8). It was also under development for the treatment of eosinophilic duodenitis, eosinophilic gastritis, eosinophilic gastroenteritis, eosinophilic esophagitis, dermatological disorders, skin and lung fibrosis.

Allakos overview

Allakos is a clinical-stage biotechnology company that develops antibodies that target immunomodulatory receptors present on immune effector cells. The company investigates the therapeutic areas of eosinophilic gastrointestinal diseases, chronic inflammatory diseases with continuing gastrointestinal symptoms along with an increase in the count of mast cells in the body. Its product offerings include AK002, an antibody that targets Siglec-8, an inhibitory receptor for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic and mastocytosis. The company is discovering AK007 to treat immuno-oncology disease. It partners with universities ad pharmaceutical companies for the manufacturing of its products. Allakos is headquartered in Redwood City, California, the US.

For a complete picture of Lirentelimab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.